Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
Decker
Thomas
T
Klinikum rechts der Isar, TU Munchen and Onkologie, Ravensburg, Germany. t.decker@lrz.tu-muenchen.de
D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011494:Protein Kinases / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases